Clinical trials: Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Steatotic Liver Disease, Fibrosis of Liver
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of…
- Trial name
- MASLD-DIAB (NCT07270822)
- Testing
- Collaborative care pathways group, Control group without intervention
- Where
- 10 sites in France
- Volunteers
- 1,714 people
- Sponsor
- Hospices Civils de Lyon
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD
Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD, Dyslipidemia, Obesity & Overweight
- Trial name
- TGP-MASLD (NCT07692438)
- Testing
- Taiwan green propolis capsule
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Thermoacoustic Method for Estimating Liver Fat Fraction
The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements.
- Trial name
- NCT07321925
- Testing
- Thermoacoustic Enhanced Ultrasound
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Endra Lifesciences
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic…
- Trial name
- NCT07902219
- Testing
- Qurse Revand
- Where
- India
- Volunteers
- 128 people
- Sponsor
- National Institute of Unani Medicine, Bengaluru
Type 2 Diabetes, Liver Disease
Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk
This clinical trial aims to find out if a digital behavioral program, delivered through the SIPPA digital therapeutics app, can help improve blood sugar control and lower the risk of liver fibrosis in adults with type 2 diabetes…
- Trial name
- SIPPA-QH_HHC-2 (NCT07032311)
- Testing
- Behavioral Treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- SIPPA Solutions INC
Steatosis of Liver
Assessment the Diagnostic Value of Pro-Neurotensin as a Serum Biomarker in MASLD
To assess the diagnostic significance of serum pro-NT in MASLD and ability to differentiate between early and advanced steatosis.
- Trial name
- NCT06453239
- Testing
- Pro-Neurotensin level as a Serum Biomarker
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops.
- Trial name
- ARTEMIS (NCT07430501)
- Testing
- Data recollection
- Where
- Spain
- Volunteers
- 7,720 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Healthy, Simple Steatosis (SS)
New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
The goal of this observational study is to learn if some components of blood or exhaled breath can diagnose people having more fat in their livers than is normal, because of their poorer metabolic health (for example, because of…
- Conditions
- Healthy, Simple Steatosis (SS), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Trial name
- NCT06647095
- Testing
- D-Limonene Gelcaps, Fish Oil Concentrate, 1000 Mg Oral Capsule
- Where
- 2 sites in Czechia
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- General University Hospital, Prague
Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
The goal of this observational study is to establish a multi-center registry to better understand Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using health screening data from Korean hospitals.
- Trial name
- K-MASLD (NCT06843421)
- Where
- 5 sites in South Korea
- Volunteers
- 6,000 people
- Sponsor
- Korea University
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Features Effects on FAST Score in MASLD Patients
The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in…
- Trial name
- NCT06867419
- Testing
- Transient Elastography
- Where
- Egypt
- Volunteers
- 385 people
- Sponsor
- Tanta University
MASLD, Cardiovascular (CV) Risk
Integrated Ultrasound-Derived Fat Fraction and 2D/4D HeartAI for Cardiovascular Risk Management in Patients With MASLD
This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult…
- Conditions
- MASLD, Cardiovascular (CV) Risk, Subclinical Cardiovascular Impairments
- Trial name
- MUCHAI (NCT07545343)
- Where
- China
- Volunteers
- 700 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in childhood is becoming increasingly prevalent, paralleling the rise in obesity rates, and has become the most common chronic liver disease in the pediatric…
- Trial name
- NCT07480811
- Testing
- DASH Diet, Standart Diet, Physical Activity
- Volunteers
- 88 people
- Sponsor
- Antalya Training and Research Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
To determine the effect of MTHF supplementation on serum folate and homocysteine level, metabolic, nutritional status, liver function, and PPARα and TNFα gene expression in patients with MASLD
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- MASLD (NCT07740109)
- Testing
- 5-methyltetrahydrofolate (5-MTHF)
- Where
- Iran
- Volunteers
- 44 people
- Sponsor
- Tabriz University of Medical Sciences
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to changes in economic conditions and lifestyle, and it is anticipated to become a significant liver disease burden in the…
- Trial name
- NCT06762223
- Testing
- Henagliflozin 10 mg daily, Metformin 1700 mg daily
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Xiqiao Zhou